Journal
CURRENT OPINION IN INFECTIOUS DISEASES
Volume 25, Issue 1, Pages 42-50Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0b013e32834ef5af
Keywords
dual infection; HIV-1; superinfection
Categories
Funding
- Gilead Sciences
- Merck Sharpe Dohme
- Boehringer Ingelheim
- ViiV Pharmaceuticals
- Janssen (a division of Johnson Johnson)
- Pfizer
- Abbott
Ask authors/readers for more resources
Purpose of review This review describes the nature and frequency of HIV-1 superinfection and provides advice regarding counselling of patients in accordance with national guidelines. Recent findings Recent studies have demonstrated conflicting results, from no superinfection to an incidence of over 18%. We discuss the difficulties comparing studies due to population and methodological differences. Summary HIV-infected individuals should be counselled that there is risk of superinfection at all stages of HIV, but this is unlikely to be clinically significant unless transmission of resistance occurs. The risk may be as high as the risk of new incident infection in the presence of on-going exposure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available